Jubilant Pharmova Ltd Share Price

Overview

Jubilant Pharmova Ltd share price is currently ₹844.78, down by - ₹14.35 (1.67%) from its previous closing price of ₹859.13. The share price has declined -14.7% over the past month and declined -21.94% over the past year. The stock's 52-week low and high are ₹774.78 and ₹1,175.77, respectively. Jubilant Pharmova Ltd has a market capitalisation of ₹ 13,710.00 Cr. The share price was last updated on 19 Aug 2026, 11:27 AM IST.

Jubilant Pharmova Ltd

JUBLPHARMA

₹0.00

- ₹14.35

1.67%

Healthcare

₹0.00(%)1D

Updated: 19 Aug 2026, 11:27:50 am IST

Market Data

Open Price

₹847.25

Prev. Close

₹859.13

₹836.35

Day Low

₹856.30

Day High

₹774.78

52 Week Low

₹1,175.77

52 Week High

HealthcarePharmaceuticals & Drugs

CategoryMid Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

37.92

Sector PE

42.16

PB Ratio

1.89

Sector PB

5.83

EPS

22.28

Dividend Yield

0.61

Today's Volume

80.825 K

5 Day Avg. Volume

198.127 K

PEG Ratio

-0.72

Market Cap.

₹ 13,710.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 500% at ₹5/Share	24-Jul-2026	24-Jul-2026
DividendsFinal Dividend of 500% at ₹5/Share	25-Jul-2025	25-Jul-2025

Mutual Fund Ownership

Mutual Fund Holder	Jun 26 Shares held	Jul 26 Shares held
Bandhan Small Cap Fund - Regular Plan - Growth	37.59 Lac	39.76 Lac (5.75%)
Quant Small Cap Fund - Growth	29.47 Lac	29.47 Lac no change
Kotak Multicap Fund - Regular Plan - Growth	18.74 Lac	18.74 Lac no change
Bandhan Focused Fund - Regular Plan - Growth	11.35 Lac	11.95 Lac (5.32%)
Kotak Contra Fund - Regular Plan - Growth	5.78 Lac	5.78 Lac no change

Show all holdings

About Jubilant Pharmova Ltd 👋

Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company's segments include Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, Proprietary Novel Drugs, and Management Services. The Radiopharma segment comprises radiopharmaceuticals, including radio pharmacies. The Contract Development and Manufacturing Organisation-Sterile Injectables segment includes contract development and manufacturing organisation-sterile injectables products. The Generics segment includes solid dosage formulations. The Contract Research, Development and Manufacturing Organisation segment includes drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment includes patient-focused biopharmaceutical businesses working to address unmet medical needs in oncology and autoimmune diseases.